| Id: | acc3561 |
| Group: | 2sens |
| Protein: | IkappaBalpha |
| Gene Symbol: | Nfkbia |
| Protein Id: | Q9Z1E3 |
| Protein Name: | IKBA_MOUSE |
| PTM: | phosphorylation |
| Site: | Ser32 |
| Site Sequence: | ERLVDDRHDSGLDSMKDEEYE |
| Disease Category: | Musculoskeletal system diseases |
| Disease: | Aseptic Loosening of Prosthesis |
| Disease Subtype: | |
| Disease Cellline: | RAW 264.7 |
| Disease Info: | |
| Drug: | Cimifugin? |
| Drug Info: | "Cimifugin is a compound with potential pharmacological activities, which is often found in some traditional Chinese medicines and has been studied for its various biological effects." |
| Effect: | modulate |
| Effect Info: | CIM can inhibit RANKL-induced osteoclastogenesis in vitro by suppressing the NF-κB signaling pathway and prevent periprosthetic osteolysis in vivo. These results suggest that CIM has potential in alkaline phosphatase (ALP) treatment. |
| Note: | |
| Score: | 4.0 |
| Pubmed(PMID): | 34658863 |
| Sentence Index: | 34658863_10-11 |
| Sentence: | "According to the Western blot analysis, inhibition of IkappaBalpha phosphorylation in the NF-kappaB signaling pathway, not the phosphorylation of MAPKs, was responsible for the suppressive effect of CIM on osteoclastogenesis. Animal experiments demonstrated that CIM alleviated Ti particle-induced bone erosion and osteoclast accumulation in murine calvaria." |
Sequence & Structure:
MFQPAGHGQDWAMEGPRDGLKKERLVDDRHDSGLDSMKDEEYEQMVKELREIRLQPQEAPLAAEPWKQQLTEDGDSFLHLAIIHEEKPLTMEVIGQVKGDLAFLNFQNNLQQTPLHLAVITNQPGIAEALLKAGCDPELRDFRGNTPLHLACEQGCLASVAVLTQTCTPQHLHSVLQATNYNGHTCLHLASIHGYLAIVEHLVTLGADVNAQEPCNGRTALHLAVDLQNPDLVSLLLKCGADVNRVTYQGYSPYQLTWGRPSTRIQQQLGQLTLENLQMLPESEDEESYDTESEFTEDELPYDDCVFGGQRLTL
No data.
No data.
Protein Tractability:
source: Open TargetsNo data.
PTM Intensity:
source: CPTACNo data.
PTM-Disease Association:
source: PTMDNo data.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
